China Traditional Chinese Medicine Holdings Co. Limited, an investment holding company, engages in the research and development, production, and sale of traditional Chinese medicine (TCM) and pharmace... China Traditional Chinese Medicine Holdings Co. Limited, an investment holding company, engages in the research and development, production, and sale of traditional Chinese medicine (TCM) and pharmaceutical products in the People's Republic of China, Hong Kong, and internationally. It operates through four segments: Yi Fang, Tian Jiang, Tong Ji Tang, and Medi-World. The company manufactures, manages, and sells concentrated TCM granules, and TCM health care products and decoction pieces, as well as TCM finished drugs. It also provides Chinese medical related healthcare solutions, including Chinese medical consultation and diagnosis, TCM physiotherapy, and prescription with concentrated TCM granules, TCM decoction pieces, and TCM healthcare product through its offline medical institutions. In addition, the company is involved in the retail sale of pharmaceuticals and decoction pharmaceutical; trading of pharmaceutical product; investment of the TCM health industry; sale of medical herb; provision of marketing, advertising and consulting of TCM; and property leasing activities. It sells its products under the Yi Fang, Tian Jiang, Tong Ji Tang, Medi-world, De Zhong, and Feng Liao Xing brands through hospitals and retail pharmacies. The company was formerly known as China Traditional Chinese Medicine Co. Limited and changed its name to China Traditional Chinese Medicine Holdings Co. Limited in 2016. China Traditional Chinese Medicine Holdings Co. Limited was founded in 1955 and is based in Wan Chai, Hong Kong.
Based on current regulatory requirements, China TCM is not required to report EU
Taxonomy data under the CSRD framework. As a result, we have not conducted a detailed EU
Taxonomy data review for this company.
If you believe this assessment should be revisited, you may submit a data coverage request
and our team will review the company's regulatory applicability.